Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E F Smit

Showing results (71-80 of 185) with videos related to

Pageof 19
Sort By:
Lung Cancer (Amsterdam, Netherlands)|June 21, 2016
Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PETI Bahce, M Yaqub, E F Smit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant scheduleH J Groen, E Fokkema, B Biesma, et al.
European Journal of Nuclear Medicine|July 20, 2000
Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methodsC J Hoekstra, I Paglianiti, O S Hoekstra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2016
Is the routine use of trimodality therapy for selected patients with non-small cell lung cancer supported by long-term clinical outcomes?C Dickhoff, K J Hartemink, J Kooij, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 4, 2018
Variability and Repeatability of Quantitative Uptake Metrics in <sup>18</sup>F-FDG PET/CT of Non-Small Cell Lung Cancer: Impact of Segmentation Method, Uptake Interval, and Reconstruction ProtocolMingzan Zhuang, David Vállez García, Gerbrand M Kramer, et al.
British Journal of Cancer|January 1, 1997
A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral bloodW Helfrich, R ten Poele, G J Meersma, et al.
The Netherlands Journal of Medicine|June 21, 2002
Failure patterns of combined modality treatment in lung cancer: the impact of stagingC J Hoekstra, H Rijna, E F Smit, et al.
EJNMMI Research|February 5, 2019
Partial-volume correction in dynamic PET-CT: effect on tumor kinetic parameter estimation and validation of simplified metricsM C F Cysouw, S V S Golla, V Frings, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2011
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatmentA Becker, L Crombag, D A M Heideman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2001
Dose-finding and pharmacological study of ifosfamide in combination with paclitaxel and carboplatin in resistant small-cell lung cancerJ W van Putten, T Kerbush, E F Smit, et al.
Pageof 19

Showing results (71-80 of 185) with videos related to

Sort By:
Pageof 19
Lung Cancer (Amsterdam, Netherlands)|June 21, 2016
Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PETI Bahce, M Yaqub, E F Smit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant scheduleH J Groen, E Fokkema, B Biesma, et al.
European Journal of Nuclear Medicine|July 20, 2000
Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methodsC J Hoekstra, I Paglianiti, O S Hoekstra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2016
Is the routine use of trimodality therapy for selected patients with non-small cell lung cancer supported by long-term clinical outcomes?C Dickhoff, K J Hartemink, J Kooij, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 4, 2018
Variability and Repeatability of Quantitative Uptake Metrics in <sup>18</sup>F-FDG PET/CT of Non-Small Cell Lung Cancer: Impact of Segmentation Method, Uptake Interval, and Reconstruction ProtocolMingzan Zhuang, David Vállez García, Gerbrand M Kramer, et al.
British Journal of Cancer|January 1, 1997
A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral bloodW Helfrich, R ten Poele, G J Meersma, et al.
The Netherlands Journal of Medicine|June 21, 2002
Failure patterns of combined modality treatment in lung cancer: the impact of stagingC J Hoekstra, H Rijna, E F Smit, et al.
EJNMMI Research|February 5, 2019
Partial-volume correction in dynamic PET-CT: effect on tumor kinetic parameter estimation and validation of simplified metricsM C F Cysouw, S V S Golla, V Frings, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2011
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatmentA Becker, L Crombag, D A M Heideman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2001
Dose-finding and pharmacological study of ifosfamide in combination with paclitaxel and carboplatin in resistant small-cell lung cancerJ W van Putten, T Kerbush, E F Smit, et al.
Pageof 19